Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

BNT-321 is under clinical development by BioNTech and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Morgan Stanley analyst Terence Flynn notes that BioNTech (BNTX) announced last week that it had reached a settlement agreement with the ...

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...

The world first became aware of Covid-19 five years ago. We evaluate where we are, remember how we got here, and consider ...

The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...

BioNTech already owned part of InstaDeep as it backed the company's $100 million Series B last year, but will take 100% control of the company if the merger goes ahead as planned.

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

Punjab State Dear 10 Diamond Tuesday Inventory of the top 50 drug sales in sample hospitals across the country in 2019 The ...

What specific content should be included in the endpoints of clinical trials of COVID-19 therapeutic drugs? Pfizer/BioNTech COVID-19 vaccine could be approved in the UK this week These major events wi ...

"Pharmaceutical Speed ​​Reading Club" Hengrui stopped the development of a large number of generic drugs, and Johnson & Johnson was asked to pay a huge amount of compensation Serious breach of trust!

INR:9641. casino real money games First NDA! Ascentage Pharmaceuticals' Category 1 new drug HQP1351 is approved for the treatment of myeloid leukemia Pfiz ...